Qfitlia does not replace the missing clotting factor. Rather, it reduces the amount of a protein called antithrombin, leading ...

Hemophilia is an inherited blood disorder in which your blood does not clot properly. This can cause you to bleed more easily and sometimes lead to excessive bleeding, even from minor cuts or ...

About 30% of people hospitalized due to acquired hemophilia have a bleeding event, while 17% have a blood clot-related ...

Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...

Medically reviewed by Steffini Stalos, DO Hemophilia disease is a rare inherited bleeding disorder. People with this genetic ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first ...

Paris: Sanofi has announced that the Company has received approval from the US Food and Drug Administration (FDA) for Qfitlia ...

PARIS, France I March 28, 2025 I The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for ...

For hemophilia C, aminocaproic acid is particularly effective at stopping bleeding from mucous membranes, including bleeding of the mouth and menstruation. It prevents blood clots from dissolving ...

Siemens Healthineers announced today its Innovance Antithrombin assay has achieved FDA clearance for a new claim allowing it ...